Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Input metadata referenced "Niagen Bioscience," but the filing text identifies the registrant as ChromaDex Corporation).
Filing Type: Form 10-Q (Quarterly Report).
Reporting Period: Three months ended April 3, 2010.
Business Overview: The Company creates and supplies botanical reference standards, phytochemical products, and related services for the functional food, pharmaceutical, personal care, and dietary supplement markets. It focuses on "green chemistry" technologies and regulatory compliance support.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $1,937,592 | $1,447,127 |
| Gross Profit | $817,973 | $468,073 |
| Gross Margin | 42.2% | 32.3% |
| Operating Income | $39,321 | ($320,192) |
| Net Income (Loss) | $33,742 | ($323,842) |
| Cash from Operations | $164,057 | ($251,311) |
| Cash and Equivalents (Ending) | $538,675 | $842,988 |
| Total Current Liabilities | $2,577,895 | $2,151,714 |
| Capital Lease Obligations | $328,773 | $74,298 |
Note: Capital Lease Obligations include current maturities ($70,750) and long-term portions ($258,023).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 34% year-over-year, driven by new service offerings, increased sales of bulk food-grade raw materials, and higher demand for existing products.
- Profitability Turnaround: The Company reported a net profit of $33,742, reversing a net loss of $323,842 in the prior year period. This was achieved through sales growth coupled with a decrease in labor and overhead costs as a percentage of sales.
- Operating Cash Flow: Operating cash flow turned positive ($164,057) compared to a negative $251,311 in the prior year, largely due to the net profit and increased accounts payable/accrued expenses.
- Debt Increase: Capital lease obligations increased significantly due to the purchase of new equipment ($264,958 incurred via non-cash investing activity).
- Margin Dynamics: While gross margin percentage improved, management notes that the shift toward high-volume, lower-margin bulk raw materials may pressure gross margins in the future.
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): On April 22, 2010, the Company entered a Subscription Agreement to sell 26,249,983 shares at $0.14/share for $3.67 million, plus warrants to purchase an equal number of shares at $0.21. Closing is subject to stockholder approval to increase authorized shares from 50 million to 150 million.
- Liquidity Outlook: Management believes current cash plus proceeds from the private placement will fund operations through December 2011. Additional financing may be required thereafter.
- Strategic Focus: Plans include expanding service capacity, implementing accreditation programs, and developing a GMP-compliant pilot plant or partnership for small-to-medium scale production.
- Regulatory Risks: The Company's demand is tied to FDA Good Manufacturing Practices (GMPs) for dietary supplements. Uncertainty regarding enforcement or interpretation of these regulations could materially affect demand.
- Dilution Risk: The proposed private placement will significantly dilute existing shareholders if consummated.
Investor Verification Checklist
- Private Placement Status: Verify if the stockholder vote to increase authorized shares (required for the $3.67M capital raise) has been approved and if the transaction has closed.
- Warrant Exercise: Assess the likelihood of investors exercising the warrants issued at $0.21/share, which would provide an additional ~$5.5 million in potential proceeds.
- Margin Sustainability: Monitor future gross margins as the company scales sales of lower-margin bulk raw materials.
- Related Party Liabilities: Note the significant "Due to officers" liability of $1,178,206 on the balance sheet; verify the terms and repayment schedule of this debt.
- Regulatory Impact: Track FDA enforcement actions regarding dietary supplement GMPs to gauge their impact on ChromaDex's reference standard demand.